Immune checkpoint inhibitors targeting the PD-1-/PD-L1 axis have been shown to be effective in relapsed or refractory NKTCL in several uncontrolled and mainly retrospective studies [14, 15]. The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.